Vitamin A supplements for reducing mother-to-child HIV transmission by Wiysonge, Charles S. et al.
Cochrane Database of Systematic Reviews
Vitamin A supplements for reducingmother-to-child HIV
transmission (Review)
Wiysonge CS, Ndze VN, Kongnyuy EJ, Shey MS
Wiysonge CS, Ndze VN, Kongnyuy EJ, Shey MS.
Vitamin A supplements for reducing mother-to-child HIV transmission.
Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD003648.
DOI: 10.1002/14651858.CD003648.pub4.
www.cochranelibrary.com
Vitamin A supplements for reducing mother-to-child HIV transmission (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
14DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 1 HIV infection
status of the child. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Analysis 1.2. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 2 Mean
birthweight. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Analysis 1.3. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 3 Low
birthweight. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Analysis 1.4. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 4 Child death by
two years of age. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Analysis 1.5. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 5 Preterm
delivery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Analysis 1.6. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 6 Stillbirth. 33
Analysis 1.7. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 7 Maternal
death. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Analysis 1.8. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 8 Postpartum
CD4 count. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
35ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
47DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
47INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iVitamin A supplements for reducing mother-to-child HIV transmission (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
[Intervention Review]
Vitamin A supplements for reducing mother-to-child HIV
transmission
Charles S Wiysonge1, Valantine N Ndze2, Eugene J Kongnyuy3, Muki S Shey4
1Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa. 2Centre for Evidence-based Health
Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 3Reproductive Health Solutions,
Salisbury, UK. 4Clinical Infectious Diseases Research Initiative (CIDRI), University of Cape Town, Health Sciences Faculty, Cape
Town, South Africa
Contact address: Charles S Wiysonge, Cochrane South Africa, South African Medical Research Council, Francie van Zijl Drive, Parow
Valley, Cape Town, Western Cape, 7505, South Africa. wiysonge@yahoo.com, charles.wiysonge@mrc.ac.za.
Editorial group: Cochrane Infectious Diseases Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 9, 2017.
Citation: Wiysonge CS, Ndze VN, Kongnyuy EJ, Shey MS. Vitamin A supplements for reducing mother-to-child HIV transmission.
Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD003648. DOI: 10.1002/14651858.CD003648.pub4.
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of
The Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial
Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used
for commercial purposes.
A B S T R A C T
Background
Strategies to reduce the risk of mother-to-child transmission of the human immunodeficiency virus (HIV) include lifelong antiretroviral
therapy (ART) for HIV-positive women, exclusive breastfeeding from birth for six weeks plus nevirapine or replacement feeding plus
nevirapine from birth for four to six weeks, elective Caesarean section delivery, and avoiding giving children chewed food. In some
settings, these interventions may not be practical, feasible, or affordable. Simple, inexpensive, and effective interventions (that could
potentially be implemented even in the absence of prenatal HIV testing programmes) would be valuable. Vitamin A, which plays a
role in immune function, is one low-cost intervention that has been suggested in such settings.
Objectives
To summarize the effects of giving vitamin A supplements to HIV-positive women during pregnancy and after delivery.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, and the World Health Organization
International Clinical Trials Registry Platform (WHO ICTRP) up to 25 August 2017, and checked the reference lists of relevant articles
for eligible studies.
Selection criteria
We included randomized controlled trials conducted in any setting that compared vitamin A supplements to placebo or no intervention
among HIV-positive women during pregnancy or after delivery, or both.
Data collection and analysis
At least two review authors independently assessed study eligibility and extracted data. We expressed study results as risk ratios (RR) or
mean differences (MD) as appropriate, with their 95% confidence intervals (CI), and conducted random-effects meta-analyses. This
is an update of a review last published in 2011.
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Main results
Five trials met the inclusion criteria. These were conducted in Malawi, South Africa, Tanzania, and Zimbabwe between 1995 and 2005
and none of the participants received ART. Women allocated to intervention arms received vitamin A supplements at a variety of doses
(daily during pregnancy; a single dose immediately after delivery, or daily doses during pregnancy plus a single dose after delivery).
Women allocated to comparison arms received identical placebo (6601 women, 4 trials) or no intervention (697 women, 1 trial). Four
trials (with 6995 women) had low risk of bias and one trial (with 303 women) had high risk of attrition bias.
The trials show that giving vitamin A supplements to HIV-positive women during pregnancy, the immediate postpartum period, or
both, probably has little or no effect on mother-to-child transmission of HIV (RR 1.07, 95% CI 0.91 to 1.26; 4428 women, 5 trials,
moderate certainty evidence) and may have little or no effect on child death by two years of age (RR 1.06, 95% CI 0.92 to 1.22; 3883
women, 3 trials, low certainty evidence). However, giving vitamin A supplements during pregnancy may increase the mean birthweight
(MD 34.12 g, 95% CI −12.79 to 81.02; 2181 women, 3 trials, low certainty evidence) and probably reduces the incidence of low
birthweight (RR 0.78, 95% CI 0.63 to 0.97; 1819 women, 3 trials, moderate certainty evidence); but we do not know whether vitamin
A supplements affect the risk of preterm delivery (1577 women, 2 trials), stillbirth (2335 women, 3 trials), or maternal death (1267
women, 2 trials).
Authors’ conclusions
Antepartum or postpartum vitamin A supplementation, or both, probably has little or no effect on mother-to-child transmission of
HIV in women living with HIV infection and not on antiretroviral drugs. The intervention has largely been superseded by ART which
is widely available and effective in preventing vertical transmission.
P L A I N L A N G U A G E S U M M A R Y
Vitamin A supplements for reducing mother-to-child transmission of HIV infection
What is the aim of this review?
The main aim of this Cochrane Review was to assess the effects of giving vitamin A supplements to HIV-positive women, during
pregnancy or after delivery, or both, on the risk of mother-to-child transmission of HIV infection. Cochrane researchers collected and
examined all relevant studies to answer this question and included five trials. This is an update of a review last published in 2011.
What is the key message of this review?
Giving vitamin A supplements to HIV-positive women, during pregnancy or after delivery, or both, probably makes little or no
difference to the risk of mother-to-child transmission of HIV (moderate certainty evidence).
What are the main results of the review?
Five trials met the inclusion criteria of the review. Two trials were from South Africa and one trial each from Malawi, Tanzania, and
Zimbabwe. The trials compared women receiving vitamin A supplements to women not receiving such supplements. None of the
participants received antiretroviral therapy (ART).
The review shows that in women living with HIV infection and not on ART:
- giving vitamin A supplements to HIV-positive women during pregnancy, immediately after delivery, or both, probably has little or no
effect on the risk of mother-to-child transmission of HIV (moderate certainty evidence) and may have little or no effect on child death
by two years of age (low certainty evidence);
- giving vitamin A supplements to HIV-positive women during pregnancy may increase the mean birthweight (low certainty evidence)
and probably reduces the number of low birthweight babies (moderate certainty evidence), but it is uncertain whether the intervention
has an effect on the number of preterm births, stillbirths, or deaths among the women (very low certainty evidence).
The intervention has largely been superseded by ART, which is widely available and effective in preventingmother-to-child transmission
of HIV.
How up-to-date is this review?
The review authors searched for studies up to 25 August 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Population: HIV-posit ive women during pregnancy and immediate postpartum period
Settings: any sett ing
Intervention: vitamin A supplements
Comparison: placebo or no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk with no
vitamin A
Correspond-
ing risk with vitamin A
supplements
HIV infect ion status of
the child
27 per 100 29 per 100
(24 to 34)
RR 1.07
(0.91 to 1.26)
4428
(5 trials)
⊕⊕⊕©
moderate1
due to imprecision
Vitamin A supplements
probably have lit t le or
no ef fect on mother-
to-child transmission of
HIV
Mean birthweight 2964 g 34 g higher
(13 g lower to 81 g
higher)
MD 34.12
(−12.79 to 81.02)
2181
(3 trials)
⊕⊕©©
low2
due to imprecision
Vitamin A supplements
may increase the mean
birthweight
Low birthweight 17 per 100 13 per 100
(11 to 17)
RR 0.78
(0.63 to 0.97)
1819
(3 trials)
⊕⊕⊕©
moderate3
due to imprecision
Vitamin A supplements
probably reduce the in-
cidence of low birth-
weight babies
Child death by two
years of age
14 per 100 15 per 100
(13 to 18)
RR 1.06
(0.92 to 1.22)
3883
(3 trials)
⊕⊕©©
low2
due to imprecision
Vitamin A supplements
may have lit t le or no ef -
fect on child death by
two years of age
Preterm delivery 20 per 100 17 per 100
(10 to 28)
RR 0.84
(0.52 to 1.37)
1577
(2 trials)
⊕©©©
very low2,4
due to imprecision and
select ive report ing
It is uncertain whether
or not vitamin A supple-
ments have an ef fect on
preterm deliveries3
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Stillbirth 3 per 100 3 per 100
(2 to 5)
RR 1.13
(0.72 to 1.77)
2335
(3 trials)
⊕©©©
very low2,4
due to imprecision and
select ive report ing
It is uncertain whether
or not vitamin A supple-
ments have an ef fect on
st illbirths
Maternal death 3 per 100 2 per 100
(1 to 4)
RR 0.71
(0.35 to 1.43)
1267
(2 trials)
⊕©©©
very low2,4
due to imprecision and
select ive report ing
It is uncertain whether
or not vitamin A supple-
ments have an ef fect on
maternal deaths
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group
and the relat ive ef fect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; g: gram; MD: mean dif ference; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1We downgraded by 1 for imprecision, as the CI ranges f rom small benef its to a clinically important increase in harm.
2We downgraded by 2 for imprecision, as the CI ranges f rom clinically important benef its to a substant ial increase in harm.
3We downgraded by 1 for imprecision, as the CI ranges f rom substant ial benef its to no ef fect.
4We downgraded by 1 for possibility of select ive report ing, because 1 or more eligible studies did not report this outcome.
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B A C K G R O U N D
Description of the condition
The Global Burden of Disease Study estimates that there were
38.8 million people living with the human immunodeficiency
virus (HIV) worldwide in 2015, half of whom were women of
childbearing age (Wang 2016). In addition, there are more than
600 new paediatric infections each day worldwide; most of which
occur in sub-Saharan Africa (UNAIDS 2015). Children mostly
acquire these infections from their mothers during pregnancy, de-
livery, or breastfeeding.
The high number of women who are of childbearing age and
who are living with HIVmakes the prevention of mother-to-child
transmission of HIV a global health priority (UNAIDS 2015).
Current strategies to reduce the risk of transmission include life-
long antiretroviral therapy (ART) to HIV-positive women, exclu-
sive breastfeeding from birth for six weeks plus nevirapine, or re-
placement feeding plus nevirapine from birth for four to six weeks
(WHO 2015), elective Caesarean section delivery (Read 2005),
and avoiding giving children chewed food. Despite their bene-
fits, these interventions are impractical in many resource-limited
countries because they require the determination of theHIV status
of pregnant women and are costly, complex, and require skilled
personnel. Simple, inexpensive, and effective interventions that
could potentially be implemented in the absence of prenatal HIV
testing programmes would be valuable. Vitamin A supplementa-
tion during pregnancy is one low-cost intervention that has been
suggested (Newell 2000).
Description of the intervention
Vitamin A refers to a group of unsaturated organic compounds
that include preformed vitamin A and provitamin A carotenoids
(Damodaran 2017). The vitamin exists as preformed retinol in an-
imal food sources, retinyl esters in fortified foods, and provitamin
A carotenoids in plant sources. Both preformed vitamin A and
provitamin A are metabolized in cells to retinal and retinoic acid,
the active forms of vitamin A, to upkeep the vitamin’s multiple
biological functions (Thorne-Lyman 2012).
The biological functions of vitamin A include the regulation and
promotion of growth and differentiation of many cells, and main-
tenance of the integrity of the epithelial cells of the respiratory and
digestive tracts. Vitamin A is necessary for formation of the photo-
sensitive visual pigment in the retina, and reproductive functions
(Wolf 2001; Tanumihardjo 2011). In the 1920s the vitamin was
considered to be an anti-infective agent (Green 1928), and there
is increasing evidence that it is essential for normal immune func-
tion (Ross 1996; Semba 1998).
Vitamin A deficiency is most prevalent in areas where diets lack
preformed vitamin A, such as in South and Southeast Asia, and
Sahel and sub-Saharan regions of Africa (West 2001). It has been
estimated that about 19 million pregnant women in low-income
countries are affected with vitamin A deficiency each year (West
2002; WHO 2009). Vitamin A deficiency in pregnant women is
associated with night blindness, severe anaemia, wasting, malnu-
trition, reproductive and infectious morbidity (Christian 1998a),
and increased risk of mortality one to two years following deliv-
ery (Christian 2000). About 10 million women suffer from night
blindness during pregnancy as a result of Vitamin A deficiency,
and this is associated with a constellation of adverse health and
nutritional conditions amongmothers and their infants (Christian
1998b; Christian 1998c; Christian 2001; WHO 2009).
How the intervention might work
In areas where poor diet and infection coexist, Vitamin A defi-
ciency can increase the severity of infection, which in turn can
reduce intake and accelerate body losses of vitamin A to exacer-
bate deficiency. Vitamin A deficiency and infection in vulnerable
groups (notably young children and pregnant or lactating moth-
ers) represent the most compelling consequences of vitamin A de-
ficiency and underlie its significance as a public health problem
around the world (WHO 2009).
Observational studies in sub-SaharanAfrica have shown low serum
vitamin A levels in HIV-positive women to be associated with sig-
nificantly increased rates of mother-to-child transmission of HIV
(Semba 1994) and infant mortality (Semba 1995). However, three
observational studies in the USA provided conflicting results: low
serum vitamin A was associated with a higher risk of mother-to-
child transmission of HIV in one study (Greenberg 1997), but not
the other two (Burger 1997; Burns 1999). These studies used dif-
ferent definitions for vitamin A deficiency: two studies used serum
retinol levels of less than30mg/dL (Greenberg 1997; Burns 1999),
and the other study used less than 20 mg/dL (Burger 1997). The
studies also had small sample sizes; for example, in Burger 1997,
only 4/95 (4.2%) of women had serum retinol levels of less than
20 mg/dL.
Vitamin A was hypothesized to decrease mother-to-child trans-
mission of HIV by acting through several maternal, foetal, child
risk factors for transmission, or all three. The proposed risk fac-
tors were the clinical, immunological, or viral stage of HIV dis-
ease among women; the integrity of the epithelial lining of the
placenta, maternal lower genital tract, or breast; the occurrence of
prematurity and low birthweight; and the status of the systemic
and digestive mucosal immune systems of the foetus and the child
(Fawzi 1998; Fawzi 2000).
Why it is important to do this review
Even though there have been dramatic reductions in the number
of newHIV infections among children (UNAIDS 2015), themag-
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nitude of the paediatric HIV epidemic in resource-limited coun-
tries is still important. The simplicity and low cost of vitamin A
supplementation makes the clarification of its role in mother-to-
child transmission of HIV of considerable importance. We aimed
to combine all high-quality randomized controlled trials (RCTs)
conducted to date to estimate the effect of vitamin A supplemen-
tation on mother-to-child transmission of HIV. This is an update
of a Cochrane Review published in 2011 (Wiysonge 2011).
O B J E C T I V E S
To summarize the effects of giving vitamin A supplements toHIV-
positive women during pregnancy and after delivery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs.
Types of participants
Pregnant or breastfeeding women, confirmed HIV-positive by a
validated laboratory test. The women could be of any age, at any
clinical stage of HIV disease, and could be living in any setting.
Types of interventions
Intervention
Vitamin A supplementation, irrespective of formulation (retinol
with or without beta-carotene), timing of supplementation (an-
tepartum, postpartum, or both), dosing, or duration of supple-
mentation. We conducted sensitivity analyses to investigate the
robustness of the results to the inclusion of trials that used beta-
carotene.
Control
Eligible comparison interventions included placebo or no inter-
vention.
Types of outcome measures
Primary outcomes
• HIV infection status of the child.
Secondary outcomes
Child
• Mean birthweight.
• Low birthweight, defined as birthweight less than 2500 g.
• Child death by two years of age.
• Preterm delivery, defined as birth at less than 37 weeks of
gestation.
• Stillbirth.
Mother
• Maternal death.
• Postpartum CD4 count.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published or unpublished) up to 25 August
2017 (Table 1).
The HIV Information Specialist, Joy Oliver, searched the
Cochrane Central Register of Controlled Trials (CENTRAL),
PubMed, Embase, Clinicaltrials.gov, and the World Health Or-
ganization International Clinical Trials Registry Platform (WHO
ICTRP) using the search strategies shown in Table 1 and Table 2.
We have also provided the search strategy for previous editions of
the review in Table 3 and Table 4.
Data collection and analysis
Two review authors evaluated study eligibility, assessed risk of bias,
and extracted data in duplicate. The two authors resolved any
disagreements by discussion and consensus. The review authors
involved in evaluating study eligibility, assessing risk of bias, and
extracting data were not blinded to the names of the trial au-
thors, their institutions, or journals of publication. We reported
the data collection and analysis procedures of previous editions
of this Cochrane Review in the previous published versions of
this review (Wiysonge 2002; Wiysonge 2005; Kongnyuy 2009;
Wiysonge 2011).
Selection of studies
Two review authors (either CSW and VNN or CSW and EJK)
screened the literature search results by title and abstract for poten-
tially relevant trials and retrieved the full-text articles as required.
The two review authors then independently assessed trial eligibil-
ity and resolved differences by discussion and consensus. We con-
sidered a trial withmultiple publications as one trial.We contacted
the corresponding authors of two potentially eligible trials to ob-
tain unpublished data (Chikobvu 2000; Friis 2004). We listed all
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studies that we excluded after full-text assessment and the reasons
for exclusion in the Characteristics of excluded studies’ table.
We constructed a PRISMA flow diagram to illustrate the study
selection process.
Data extraction and management
Two review authors (CSWandVNN,CSWandEJK, orCSWand
MSS) extracted information on study methods, participants, in-
terventions, and outcomes from each included trial, and reported
this information in the Characteristics of included studies’ ta-
ble.
Assessment of risk of bias in included studies
For each included trial, two review authors (CSW and VNN,
CSW and EJK, or CSW andMSS) independently assessed the risk
of bias by addressing seven prespecified domains (Higgins 2011):
generation of the randomization sequence, concealment of the
allocation of interventions, blinding of participants and personnel,
blinding of outcome assessment, completeness of outcome data,
completeness of outcome reporting, and any other concerns.
We described what the trial authors reported that they did for
each domain and then decided the risk of bias for that domain
by assigning a judgement of low’, high’, or unclear’ risk of
bias. We summarized the risk of bias for each trial as either low
or high. We classified any trial that had a high risk of bias linked
to allocation concealment, blinding of outcome assessment, or
completeness of outcome data as having a high risk of bias. We
considered all other trials to have low risk of bias.
Measures of treatment effect
We expressed each study result as the risk ratio (RR) for dichoto-
mous data or the mean difference (MD) for continuous data, with
95% confidence intervals (CIs).
Unit of analysis issues
There were no unit of analysis issues in this Cochrane Review, as
all eligible trials were individually randomized.
Dealing with missing data
We conducted a complete-case analysis such that we included all
participants with a recorded outcome in the analyses. We have re-
ported allmissingdata and trial dropouts (see the Characteristics
of included studies’ table). One trial reported results as means
with their standard errors (SE) instead of standard deviations (SD)
(Kumwenda 2002). We calculated the SD using the following for-
mula: SD = (square root of N) x (SE).
Assessment of heterogeneity
We assessed the heterogeneity of effects across included trials by
visually inspecting the graphical display of data in forest plots and
using the Chi² test of homogeneity. In the presence of significant
statistical heterogeneity, defined as P < 0.1, we first checked data
accuracy to exclude data capturing errors. We quantified observed
heterogeneity using the Higgins I² statistic.
Assessment of reporting biases
If we had 10 or more trials included in a meta-analysis, we would
have used funnel plots to assess the risk of publication bias. In
such circumstances, we would have assessed the funnel plot vi-
sually, followed by formal statistical tests to assess any observed
funnel plot asymmetry (Egger 1997; Harbord 2006). Apart from
reporting biases, potential causes of funnel plot asymmetry may
include high risk of bias, true heterogeneity of effects, and chance
(Higgins 2011).
Data synthesis
We used both unpublished (Chikobvu 2000), and published data
(Coutsoudis 1999; Fawzi 2002; Kumwenda 2002; Humphrey
2006), to analyse trial participants in groups to which they were
randomized, regardless of which or how much treatment they
actually received.
Two trials used two-by-two factorial designs (Fawzi 2002;
Humphrey 2006).
In the first trial, women and their newborns were recruited within
four days of delivery and randomly assigned to four treatment
groups: Aa, Ap, Pa, and Pp. “A” was maternal vitamin A supple-
mentation, “P” was maternal placebo, “a” was infant vitamin A
supplementation, and “p” was infant placebo (Humphrey 2006).
In this Cochrane Review, we only used data from Ap (interven-
tion) versus Pp (placebo).
In the second trial with a two-by-two factorial design, preg-
nant women were randomly assigned to receive either “vitamin
A alone”, “vitamin A plus multivitamins”, “multivitamins with-
out vitamin A”, or “placebo” (Fawzi 2002). Although the trial au-
thors stated that there was no evidence of clinical interaction be-
tween vitamin A and multivitamins, our plan was to consider only
the “vitamin A alone” arm as the intervention. However, in the
multiple publications from this trial, separate data for “vitamin
A alone” were only available for low birthweight and maternal
deaths. Thus, for the other outcomes we used data as reported by
the trial authors, that is, vitamin A (a combination of “vitamin A
alone” and“vitamin A plusmultivitamins” arms) versus no vitamin
A (consisting of “multivitamins without vitamin A” and “placebo”
arms).
We conducted random-effectsmeta-analyses inRevMan5 because
of the diversity of study designs, type of intervention (that is, pre-
formed vitamin A with or without beta-carotene), timing of inter-
vention (that is, antepartum supplementation, postpartum sup-
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plementation, or both), dosing of the supplements, and compari-
son groups (that is, placebo or no intervention) (RevMan 2014).
We also calculated the optimal information size for the outcomes
and presented this information in Table 5. In addition, we used
the GRADE approach to assess the certainty of the evidence for
the effect of vitamin A supplementation on each key outcome
(Guyatt 2008). We constructed a Summary of findings’ table
using GRADEpro software (GRADEpro GDT 2015).
Subgroup analysis and investigation of heterogeneity
For the primary outcome, we conducted a subgroup analysis based
on the timing of vitamin A supplementation, that is antepartum
supplementation (Chikobvu 2000; Kumwenda 2002), postpar-
tum supplementation (Humphrey 2006), or both (Coutsoudis
1999; Fawzi 2002).
Sensitivity analysis
We included trials that provided supplements containing only pre-
formed vitamin A (Chikobvu 2000; Kumwenda 2002;Humphrey
2006), and trials that used both preformed vitamin A (retinol)
and a provitamin A carotenoid (beta-carotene) (Coutsoudis 1999;
Fawzi 2002).
Beta-carotene is easily converted to retinol, but also has antiox-
idative properties (Thorne-Lyman 2012).We therefore conducted
sensitivity analyses to investigate the robustness of the results on
the primary outcome to the type of intervention (that is, we omit-
ted trials that used beta-carotene).
R E S U L T S
Description of studies
Results of the search
Figure 1 shows the search and study selection process for this
Cochrane Review, in line with the PRISMA statement (Moher
2009).
Figure 1. PRISMA flow diagram
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Of the five trials included in the previous version of this review,
Wiysonge 2011, we retained four of the previously included tri-
als (Coutsoudis 1999; Fawzi 2002; Kumwenda 2002; Humphrey
2006), and excluded one trial because further assessment revealed
that it did not meet our inclusion criteria (Friis 2004). We ob-
tained unpublished data for one ongoing trial (Chikobvu 2000).
Of the 159 records identified from the updated literature search,
we excluded 158 and identified one new article to add to an al-
ready included study.
Included studies
Five trials met the inclusion criteria (see Figure 1 and the
Characteristics of included studies’ table). These include a trial
that we classified as ongoing in previous published versions of this
review (Chikobvu 2000). The trial was conducted fromSeptember
1997 toDecember 2000 in South Africa, and the principal investi-
gator of the trial has provided us with outcome data on mother-to-
child transmission of HIV (Chikobvu 2000). We briefly describe
below the designs, participants, interventions, comparisons, and
outcome measures of the five included trials.
Period of study
These five included trials were conducted between 1995 and 2005,
at the height of the HIV epidemic in sub-Saharan Africa.
Design
Three of the included trials were randomized trials (Fawzi 2002;
Kumwenda 2002; Humphrey 2006). Two trials were described as
randomized trials, but the trial authors did not describe the meth-
ods used to generate the randomization sequence (Coutsoudis
1999; Chikobvu 2000). Two trials had two-by-two factorial de-
signs (Fawzi 2002; Humphrey 2006). All trials used participants
as units of randomization. The proportion of participants lost to
follow-up ranged from 3.2% (Humphrey 2006), to more than
48% (Chikobvu 2000). All trial authors excluded mother-infant
pairs lost to follow-up from their analyses.
Location
The five trials were conducted in four countries in sub-Saharan
Africa: Malawi (one trial; Kumwenda 2002), South Africa (two
trials; Coutsoudis 1999; Chikobvu 2000), Tanzania (one trial;
Fawzi 2002), and Zimbabwe (one trial; Humphrey 2006).
Population
In trials with antepartum vitamin A supplementation, participants
consisted of HIV-positive pregnant women recruited during their
first antenatal visit (Chikobvu 2000), 12 to 27 weeks’ gestation
(Fawzi 2002), 18 to 28 weeks’ gestation (Kumwenda 2002), and
17 to 39 weeks’ gestation (Coutsoudis 1999). For the single trial
of postpartum vitamin A supplementation, HIV-positive women
were recruited within 96 hours of delivery (Humphrey 2006).The
prevalence of vitamin A deficiency among the women at baseline
was 30.6% in Coutsoudis 1999, 34% in Fawzi 2002, and 51% in
Kumwenda 2002; but was not reported in two trials (Chikobvu
2000; Humphrey 2006).
Interventions
Vitamin A supplements
Three trials used supplements that contained retinol alone (
Chikobvu 2000; Kumwenda 2002; Humphrey 2006), and two
trials used both retinol and beta-carotene (Coutsoudis 1999; Fawzi
2002).
Two trials provided vitamin A supplements to women only dur-
ing pregnancy (Chikobvu 2000; Kumwenda 2002). One trial pro-
vided vitamin A during pregnancy, but did not report information
on the type or dose of vitamin A used (Chikobvu 2000). The sec-
ond trial provided pregnant women in the intervention arm with
10,000 IU daily oral doses of vitamin A (Kumwenda 2002).
One trial provided vitamin A supplements only after delivery
(Humphrey 2006). This trial had a factorial design and the inter-
ventions consisted of a single oral dose of 400,000 IU vitamin A
to the mother only; 50,000 IU single oral dose to the newborn
only; or 400,000 IU to the mother and 50,000 IU to the newborn
(Humphrey 2006). In our analyses, we considered only the group
in which the mother alone received vitamin A supplements as the
intervention arm.
In two trials, women received vitamin A supplements both dur-
ing pregnancy and immediately after delivery (Coutsoudis 1999;
Fawzi 2002). In the first trial, women in the intervention arm re-
ceived 5000 IU retinyl palmitate and 30 mg beta-carotene daily
during pregnancy. In addition, at delivery, women in the inter-
vention arm received 200,000 IU of retinyl palmitate (Coutsoudis
1999). The second trial employed a two-by-two factorial design
(Fawzi 2002). Women in the intervention arms received daily
doses of vitamin A (30 mg beta carotene plus 5000 IU retinyl
palmitate) alone; vitamin A plus multivitamins (20 mg vitamin
B1, 20 mg vitamin B2, 25 mg vitamin B6, 100 mg niacin, 50
µg vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8
mg folic); or multivitamins alone. At delivery, women receiving
any vitamin A were given an additional 200,000 IU oral dose of
vitamin A (Fawzi 2002).
Concomitant interventions
Two trials did not provide information on any concomitant in-
terventions (Coutsoudis 1999; Chikobvu 2000). In the remain-
ing three trials, the pregnant women received daily oral doses of
iron and folic acid (Fawzi 2002; Kumwenda 2002; Humphrey
2006). One trial also reported providing weekly doses of chloro-
quine (Fawzi 2002), and another trial provided all women with
9Vitamin A supplements for reducing mother-to-child HIV transmission (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
oral vitamin A (100,000 IU) at six weeks postpartum, according
to national policy (Kumwenda 2002). In one trial all children,
regardless of whether they were in the intervention or compar-
ison arm, received 100,000 IU vitamin A at six months of age
and 200,000 IU of vitamin A every six months afterwards (Fawzi
2002).
Antiretroviral therapy (ART)
None of the five included trials reported giving ART to partici-
pants.
Comparison interventions
In four trials, the comparison intervention was a placebo (
Coutsoudis 1999; Chikobvu 2000; Fawzi 2002; Humphrey
2006). The fifth study used a “no intervention” comparison group
(Kumwenda 2002). All women in this trial received iron and folic
acid, and half of them were randomly assigned to receive vitamin
A. Supplements that contained vitamin A, iron, and folic acid were
indistinguishable from the ones that contained only iron and folic
acid (Kumwenda 2002).
Outcome measures
Primary outcomes
HIV infection status of the child
We obtained data on children’s HIV infection status at three
months (Coutsoudis 1999; Chikobvu 2000), and at 24 months
(Fawzi 2002; Kumwenda 2002; Humphrey 2006). A child was
determined to be HIV-positive when a blood specimen tested
positive using polymerase chain reaction (PCR) at any point or
a plasma specimen obtained at 18 months of age or older tested
positive using enzyme-linked immunosorbent assay (ELISA).
Secondary outcomes
Birthweight
Three trials reported data onmean birthweight (Coutsoudis 1999;
Fawzi 2002; Kumwenda 2002).
Child death by two years of age
Three trials reported data on child death by 24 months of age
(Fawzi 2002; Kumwenda 2002; Humphrey 2006).
Low birthweight
Three trials reported data on the occurrence of low birth-
weight, that is, children born with birthweight less than 2500g
(Coutsoudis 1999; Fawzi 2002; Kumwenda 2002).
Preterm delivery
Two trials reported data on preterm deliveries, that is, births at less
than 37 weeks of gestation (Coutsoudis 1999; Fawzi 2002).
Stillbirth
Three trials reported data on stillbirths (Coutsoudis 1999; Fawzi
2002; Kumwenda 2002).
Maternal death
One trial reported data on maternal deaths from any cause by
three months after delivery (Coutsoudis 1999). The second trial
reported data on maternal deaths fromAIDS-related causes at two
and four years (Fawzi 2002). We have used the two-year data in
this review.
Postpartum CD4 count
One trial reported postpartum CD4 cell count at two and four
years (Fawzi 2002). We have used the two-year data in this review.
Excluded studies
We included Friis 2004 in the previous version of this review
(Wiysonge 2011), but excluded the study from this review update
because the intervention consisted of multivitamins (including vi-
tamin A) rather than vitamin A alone. We identified 159 records
from literature searches. We excluded 155 records after screening
by title/abstract. Of the four remaining studies, we excluded three
studies after full-text assessment (Duggan 2012; Olofin 2016;
Locks 2017), and identified one new reference to an already in-
cluded study. We excluded the remaining three studies because
they assessed the effects of multivitamins (and not vitamin A) and
had as participants, children born to HIV-positive women (rather
than the women themselves) (Duggan 2012; Olofin 2016; Locks
2017).
Risk of bias in included studies
We have provided detailed Risk of bias’ assessments of the in-
cluded trials in the Characteristics of included studies’ table,
and provided a summary in Figure 2 and Figure 3.
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Figure 2. Risk of bias’ graph: review authors’ judgements about each Risk of bias’ item presented as
percentages across all included trials
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Figure 3. Risk of bias’ summary: review authors’ judgements about each Risk of bias’ item for each
included trial
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Allocation
Sequence generation
Regarding sequence generation, three trials were at low risk of bias
(Fawzi 2002; Kumwenda 2002; Humphrey 2006), and the risk of
bias in two trials was unclear (Coutsoudis 1999; Chikobvu 2000).
The authors of the latter trials did not clearly describe themethods
used to generate the randomization sequence (Coutsoudis 1999;
Chikobvu 2000).
Allocation concealment
Three trials were at low risk of bias as per allocation concealment
(Fawzi 2002; Humphrey 2006; Kumwenda 2002).We judged two
trials to have an unclear risk of bias (Coutsoudis 1999; Chikobvu
2000), as the trial authors did not describe the methods used to
conceal allocation to intervention and comparison groups.
Blinding
All five trials were at low risk of performance bias because partici-
pants and care providers were blinded to treatment allocation.
The five included trials performed blinding of outcome assessors,
thus we judged them to be at low risk of detection bias.
Incomplete outcome data
Four trials had low risk of bias in relation to completeness of
outcome data (Coutsoudis 1999; Fawzi 2002; Kumwenda 2002;
Humphrey 2006), but we judged one trial to be at high risk of
bias (Chikobvu 2000). The proportion of participants lost to fol-
low-up was 3.2% in Humphrey 2006, 5.0% in Fawzi 2002, 7.8%
in Coutsoudis 1999, 9.0% in Kumwenda 2002, and more than
48% in Chikobvu 2000. Therefore, the proportion of random-
ized participants with evaluable data ranged from less than 52%
(Chikobvu 2000), to 96.8% (Humphrey 2006).
Selective reporting
We judged the risk of reporting bias to be low in four trials
(Coutsoudis 1999; Fawzi 2002; Kumwenda 2002; Humphrey
2006). However, we observed evidence of selective reporting in
one trial, which we judged to be at high risk of reporting bias
(Chikobvu 2000). The trial did not report data onmother-to-child
transmission of HIV because of high loss to follow-up (Chikobvu
2000).
Other potential sources of bias
We observed no other potential sources of bias in included studies.
Summary of ’Risk of bias’ assessment
Overall, four trials (with 6995 women) were at low risk of bias
(Coutsoudis 1999; Fawzi 2002; Kumwenda 2002; Humphrey
2006), and one trial (with 303 women) was at high risk of bias
(Chikobvu 2000).
Effects of interventions
See: Summary of findings for the main comparison Effects of
giving vitamin A supplements to HIV-positive women during
pregnancy or after delivery
We have summarized the effects of vitamin A supplementation of
HIV-positive women during pregnancy, immediately after deliv-
ery, or both, on key outcomes in the Summary of findings’ table
(Summary of findings for the main comparison).
Primary outcome
HIV infection status of the child
The risk ratio for the effect of vitamin A supplementation dur-
ing pregnancy on mother-to-child transmission of HIV was 0.85
(95% CI 0.67 to 1.09; 650 women, 2 trials) and for vitamin A
supplementation immediately after delivery was 1.11 (95% CI
0.98 to 1.09; 2248 women, 1 trial). In the two trials that provided
vitamin A supplementation to women during pregnancy and im-
mediately after delivery, the RR was 1.17 (95% CI 0.86 to 1.59;
1530 women, 2 trials).
Overall, the trials show that vitamin A supplementation of HIV-
positive women during pregnancy or the immediate postpartum
period, or both, probably has little or no effect on the risk of
mother-to-child transmission of HIV (RR 1.07, 95% CI 0.91 to
1.26; 4428 women, 5 trials, moderate certainty evidence). There
were no substantial differences in effects across the three subgroups
(heterogeneity P = 0.15, I² statistic = 48.1%; Analysis 1.1).
The effects were similar between studies that provided supple-
ments containing only retinol (RR 1.00, 95% CI 0.81 to 1.22;
2898 women, 3 trials) and those that provided both retinol and
beta-carotene (RR 1.17, 95% CI 0.86 to 1.59; 1530 women, 2
trials).
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Secondary outcomes
Child
Birthweight
Vitamin A supplementation of HIV-positive women during preg-
nancy may increase the mean birth weight of babies (MD 34.12
g, 95% CI−12.79g to 81.02; 2181 women, 3 trials, low certainty
evidence). The effect was fairly consistent across the three trials
(heterogeneity P = 0.34, I² statistic 8%; Analysis 1.2).
Low birthweight
Vitamin A supplementation of HIV-positive pregnant women
probably reduces the incidence of low birthweight (RR 0.78, 95%
CI 0.63 to 0.97; 1819 women, 3 trials, moderate certainty evi-
dence). The effect was homogenous across the three included trials
(heterogeneity P = 0.56; I² statistic = 0%; Analysis 1.3).
Child death by two years of age
Vitamin A supplementation of HIV-positive women during preg-
nancy or the immediate postpartum period, or both, may have
little or no effect on child death by two years of age (RR 1.06, 95%
CI 0.92 to 1.22; 3883 women, 3 trials, low certainty evidence).
This finding was consistent across the three studies (heterogeneity
P = 0.49, I² statistic = 0%; Analysis 1.4).
Preterm delivery
It is uncertain whether vitamin A supplementation of HIV-posi-
tive pregnant women has an effect on the risk of preterm deliveries
(RR 0.84, 95% CI 0.52 to 1.37; 1577 women, 2 trials, very low
certainty evidence). There was unexplained heterogeneity of effects
between the two studies (heterogeneity P = 0.03, I² statistic = 79%;
Analysis 1.5).
Stillbirth
It is uncertain whether vitamin A supplementation of HIV-posi-
tive pregnant women has an effect on the incidence of stillbirths
(RR 1.13, 95% CI 0.72 to 1.77; 2335 women, 3 trials, very low
certainty evidence). This uncertainty was consistent across the three
trials (heterogeneity P = 0.80, I² statistic = 0%; Analysis 1.6).
Mother
Maternal death
It is uncertain whether vitamin A supplementation of HIV-posi-
tive women during pregnancy and immediate postpartum period
has an effect on maternal deaths, as the certainty of the evidence
was very low (RR 0.71, 95% CI 0.35 to 1.43; 1267 women, 2
trials). This finding was consistent between the two trials (hetero-
geneity P = 0.75, I² statistic = 0%; Analysis 1.7).
Postpartum CD4 count
It is uncertain whether vitamin A supplementation of HIV-posi-
tive women during pregnancy and immediate postpartum period
has an effect on postpartum maternal CD4 levels, as the certainty
of the evidence was very low (mean difference −13.00, 95% CI
−60.46 to 34.46; 511 women, 1 trial; Analysis 1.8).
D I S C U S S I O N
Summary of main results
Five randomized trials, which were conducted between 1995 and
2005 and included 7298 HIV-positive women in sub-Saharan
Africa, met the inclusion criteria of this Cochrane Review. The
included trials assessed the effects of vitamin A supplementation
during pregnancy, immediately after delivery, or both. A synthesis
of the results of the trials shows that vitamin A supplementation
probably has little or no effect on mother-to-child transmission
of HIV (moderate certainty evidence) and may have little or no ef-
fect on child death by two years of age (low certainty evidence).
However, vitamin A supplements may increase the mean birth-
weight (low certainty evidence) and probably reduce the incidence
of low birthweight (moderate certainty evidence). Due to very low
certainty evidence it is uncertain whether vitamin A supplements
have an effect on preterm delivery, stillbirth, or maternal death.
Overall completeness and applicability of
evidence
By the end of the 20th century, HIV had produced a global epi-
demic that was far more extensive than was predicted when the
infection emerged less than two decades earlier. Antenatal sero-
prevalence of HIV was more than 10% in many countries in sub-
Saharan Africa, the risk of mother-to-child transmission of HIV
was about 30% to 45% in the region, and the region was con-
tributing more than 90% of the nearly 2000 new HIV infections
in children each day worldwide (De Cock 2000; UNAIDS 2001).
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In this context, it was estimated that even with a 3% reduction in
transmission, vitamin A supplementation of HIV-positive women
would be a cost-effective method of preventing mother-to-child
transmission of HIV. Vitamin A supplements are easily provided
through existing health services (Wiysonge 2006). It was thus nec-
essary to clarify the effect of the vitamin on mother-to-child trans-
mission of HIV. Such clarification was judged to be important
to decision-makers considering affordable options for reducing
mother-to-child transmission of HIV in resource-limited settings
(Wiysonge 2002).
Despite our comprehensive search, we found only six potentially
eligible trials on the topic, of which five trials met our inclusion
criteria. Our review shows that vitamin A supplementation of
HIV-positive women during pregnancy, after delivery, or both,
probably has little or no effect on mother-to-child transmission of
HIV.
Our data suggest that the association between low serum vita-
min A levels and increased risk of mother-to-child transmission of
HIV seen in observational studies (Semba 1994;Greenberg 1997),
could have other explanations. Given the observational design of
such studies, residual confounding by advanced HIV infection
or other factors may explain the seemingly protective association
(Fawzi 1998).
In high-income countries, the combination of (1) antiretroviral
prophylaxis, (2) elective Caesarean section delivery, and (3) for-
mula feeding in clinical practice, coupled with increased prenatal
HIV counselling and testing, has essentially eliminated mother-
to-child transmission of HIV in those settings (Mofenson 2000;
Navér 2006; UNAIDS 2015). Due to cost and other constraints,
many countries in sub-Saharan Africa had difficulties implement-
ing these interventions (McIntyre 2002). However, in the last
decade, there have been dramatic improvements. Antiretroviral
drugs are now widely available in sub-Saharan Africa and other re-
source-constrained settings (UNAIDS 2015; WHO 2015; Wang
2016).
Vitamin A is teratogenic when consumed at high doses during
early pregnancy, but none of the trials included in this review
reported information on adverse events. However, the doses of
vitamin A used in the trials were within the recommended safe
low doses (WHO 1998).
Quality of the evidence
Due to the inconsistency of the effect of vitamin A supplementa-
tion on mother-to-child of HIV across included trials, we down-
graded the certainty of this evidence to moderate. The GRADE
Working Group classifies research evidence as being of moderate
certainty if the true effect of the intervention is likely to be close
to what was found in the research but there is a possibility that
it is substantially different (Guyatt 2008). Therefore, this review
does not completely exclude the possibility of a small beneficial
or harmful effect of vitamin A supplementation on the risk of
mother-to-child of HIV.
For most of the other outcomes assessed, we judged the certainty
of the evidence to be very low (Summary of findings for the
main comparison), implying that we are uncertain about the true
effect of vitamin A supplementation on these outcomes. Ourmain
concerns with the evidence were imprecision (as the CIs ranged
from large benefits to clinically important increases in harm) and
the possibility of publication bias (because two or more eligible
trials did not report the outcomes).
Potential biases in the review process
We minimized bias in the process of conducting and reporting
the review by adhering to the Methodological Expectations of
Cochrane Intervention Reviews (MECIR) (Higgins 2016).
The ultimate goal of this review was to determine whether vi-
tamin A supplementation of HIV-positive women could be rec-
ommended as a public health policy to reduce mother-to-child
of HIV. We therefore considered overall mother-to-child of HIV,
whether occurring during pregnancy, during delivery, or after
birth. As such we pooled data from all studies, subgrouped by the
timing of supplementation. We do not think that pooling data
from these trials has introduced bias to the review.
Agreements and disagreements with other
studies or reviews
We found that vitamin A supplements probably make little or
no difference to the risk of mother-to-child transmission of HIV.
This finding is consistent with the findings of previous reviews
of maternal vitamin A supplementation by our team (Wiysonge
2002; Wiysonge 2005; Kongnyuy 2009; Wiysonge 2011), and
others (Thorne-Lyman 2012).
Our review also shows that giving vitamin A supplements dur-
ing pregnancy or the immediate postpartum period, or both, may
have little or no effect on child death by two years of age. This
finding is consistent with that of other authors (Gorgia 2010;
Thorne-Lyman 2012). In a previous systematic review, Gorgia
2010 pooled data from six randomized trials and found little or
no effect on infant mortality of giving synthetic vitamin A sup-
plements to seemingly healthy mothers after delivery.
In another review, Thorne-Lyman 2012 pooled data from 17 tri-
als among women of any HIV status and found little or no ef-
fect of antepartum retinol and beta-carotene supplements on in-
fant mortality. As in this Cochrane Review, Thorne-Lyman 2012
found that antepartum supplementation was protective against
low birthweight among HIV-positive women.
Vitamin A is important for embryogenesis; playing a vital role in
the development of the foetal heart, embryonal circulatory system,
and the regulation of heart asymmetry (Zile 1998). This role could
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explain the substantial reduction in low birthweight in the vitamin
A group compared to placebo or no intervention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Antepartum or postpartum vitamin A supplementation, or both,
probablymakes little or nodifference to the risk ofmother-to-child
transmission of HIV. The evidence from this Cochrane Review
suggests that giving vitamin A supplements to pregnant HIV-
positive women may have beneficial effects on birthweight.
Implications for research
Given that the currently available randomized trial data do not
exclude the possibility that vitamin A supplementation could have
small beneficial or harmful effects on mother-to-child transmis-
sion of HIV, there may be need for an appropriately powered
randomized trial to assess the additive effect of the interven-
tion in antiretroviral-treated women. However, with the current
widespread use and success of antiretroviral therapy (ART) in re-
ducing mother-to-child transmission of HIV, further research on
the use of vitamin A supplements for this indication may not be
warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chikobvu 2000
Methods Randomized controlled trial (RCT)
Participants 303 HIV-positive pregnant women from metropolitan Bloemfontein, South Africa.
Most participants (56%) lived in informal settlements and all attended public health
facilities. For the trial, women were asked to volunteer for HIV testing during their first
antenatal visit. Pretest counselling was done in groups, and post-test counselling was
done individually. Women who were seropositive for HIV were asked to participate in
the trial
Interventions Vitamin A supplementation versus placebo
Outcomes Mother-to-child transmission (MTCT) of HIV
Notes All trial participants gave separate informed consent for the trial. All patients were re-
cruited by one study physician and received verbal or written information (Sesotho,
English, or Afrikaans information sheets)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not mention the method
used to generate the randomization sequence
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the method
used to conceal the treatment allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial used an identical placebo;HIVdiagnosis
was done in the laboratory
Incomplete outcome data (attrition bias)
All outcomes
High risk More than 48% of women were lost to follow-up
and we do not know whether this was related to
outcomes
Selective reporting (reporting bias) High risk Not all prespecified outcomes were reported in
various publications from this trial
Other bias Low risk We do not believe that other biases were intro-
duced, over and above the high loss to follow-up
and the selective reporting
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Coutsoudis 1999
Methods Described as randomized double-blind.
The trial authors lost eight per cent ofmother-infant pairs during follow-up and excluded
them from the analysis
Participants 728 HIV-positive women enrolled at 17 to 39 weeks’ gestation in KwaZulu-Natal
Province of South Africa; 30.6% of whom had serum retinol levels < 20 µg/dL
Interventions Daily oral vitamin A (5000 IU retinyl palmitate and 30 mg beta-carotene) or placebo.
At delivery, women in the vitamin A group received a dose of 200,000 IU of retinyl
palmitate while the placebo arm received an identical placebo
Outcomes Stillbirths, HIV infection in the child, neonatal deaths, preterm birth, birthweight, low
birthweight
Notes No woman received any antiretroviral therapy (ART). It is not stated in the trial reports
whether the women also received iron or folic acid, or both
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method used to generate the randomiza-
tion sequence
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method used to conceal the treatment allo-
cation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Use of identical placebo; diagnosis of HIV
was done in the laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 10% of women were lost to fol-
low-up and we do not believe that this was
related to the outcome. We do not believe
this introduced bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
various publications from this trial
Other bias Low risk We do not believe that other biases were
introduced that could have affected study
findings
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Fawzi 2002
Methods Randomized, placebo-controlled, double-blind.
The trial authors lost five per cent of mother-infant pairs during follow-up and excluded
them from the analysis
Participants 1075 pregnant HIV-positive women enrolled at 12 to 27 weeks’ gestation in Dar es
Salam, Tanzania. Of 1085 women initially randomized, 10 were eventually excluded for
either being HIV-negative (n = 7) or not pregnant (n = 3). The prevalence of vitamin A
deficiency (< 0.70 µmol/L) was about 34% during the second trimester
Interventions Daily oral dose of one of: vitamin A (30 mg beta carotene + 5000 IU retinyl palmitate)
alone, multivitamins (20 mg vitamin B1, 20 mg vitamin B2, 25 mg vitamin B6, 100
mg niacin, 50 µg vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic)
plus vitamin A, multivitamins without vitamin A, or placebo
At delivery, women receiving any vitamin A were given an additional 200,000 IU oral
dose of vitamin A while the others received an extra dose of placebo
In this review, we used only data from the vitamin A only (intervention) and the placebo
arms
Outcomes Stillbirths, HIV infection in child, preterm delivery, low birthweight, postpartum CD4
levels
Notes It is not mentioned in this trial whether any woman received ART. All women were given
daily oral doses of iron and folic acid, and weekly doses of chloroquine. All children,
regardless of which intervention group they were in, received 100,000 IU vitamin A at
six months of age, and 200,000 IU of vitamin A every six months afterwards
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used computer-generated ran-
domization sequence.
Allocation concealment (selection bias) Low risk Block randomization; blocks of 20. At en-
rolment, the investigators assigned each el-
igible woman the next numbered bottle of
study drug
Blinding (performance bias and detection
bias)
All outcomes
Low risk At enrolment, each eligible woman was as-
signed the next numbered bottle of study
drug. Active tablets and placebo were in-
distinguishable, so that neither the partic-
ipants nor the investigators could identify
which participants were randomized to the
which regimen
Incomplete outcome data (attrition bias)
All outcomes
Low risk Fifty-four women (5.0%) were lost to fol-
low-up, and we do not believe that this was
related to the outcome. We do not believe
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Fawzi 2002 (Continued)
this introduced bias
Selective reporting (reporting bias) Low risk The trial authors reported on all outcomes
specified in the goals of the study articles
Other bias Low risk We do not believe that other biases were in-
troduced that could have affected the study
findings
Humphrey 2006
Methods Randomized, placebo-controlled trial.
Participants 4495 mother-infants pairs who were part of the Zimbabwe Vitamin A for Mothers and
Babies (ZVITAMBO) trial in Harare Zimbabwe. Mother-infant pairs were enrolled at
96 hours (or less) after delivery
Interventions A 2-by-2 factorial design with 4 treatment groups Aa, Ap, Pa, and Pp; where “A” was
maternal vitamin A supplementation (400,000 IU), “P” was maternal placebo, “a” was
infant vitamin A supplementation (50,000 IU), and “p” was infant placebo
In this review, we used only data from Ap (intervention) versus Pp (placebo)
Outcomes Primary outcome: breastfeeding-associated MTCT and HIV-free survival
Secondary outcome: adverse effects in HIV-positive women or their infants
Notes All but 4 mothers initiated breastfeeding, no information on ART or cotrimoxazole
prophylaxis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors performed randomization us-
ing computer-generated blocks of 12
Allocation concealment (selection bias) Low risk Treatment assignment was concealed by pre-
packing study supplements in sequentially
numbered series assigned to study identifica-
tion numbers. Concealed envelopes with study
number; link between number and treatment
assignment kept at central location
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, care providers, and outcome as-
sessors were blinded to the treatment alloca-
tion. Mothers were assigned an original study
identification number at enrolment and were
given the next sequentially numbered opaque
bottle with supplements
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Humphrey 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk One hundred and forty-three (3.2%) mother-
infant pairs were lost to follow-up. We do not
believe that the loss to follow-up was related to
the outcome
Selective reporting (reporting bias) Low risk The trial authors reported outcomes that were
prespecified in the protocol (NCT00198718)
Other bias Low risk We do not believe that other biases were intro-
duced that could have affected the study find-
ings
Kumwenda 2002
Methods RCT. Participants were assigned to treatment using computer-generated random num-
bers, and treatment was concealed by pre-packing study supplements in sequentially
numbered series assigned to study identification numbers. Sixty-three women (9%) were
lost to follow-up before delivery and excluded from the analyses. The 14 pairs of twins
in the study were excluded from the birth weight and mortality analyses because twins
are known to have lower birth weights and higher mortality rates
Participants 697 pregnant HIV-positive women enrolled at 18 to 28 week’s gestation in Blantyre,
Malawi. The prevalence of vitamin A deficiency (< 0.70 µmol/L) was 51% during the
second trimester
Interventions All women received orally administered daily doses of iron (30 mg of elemental iron) and
folate (400 µg) from enrolment until delivery. One-half of the women were randomized
to receive daily doses of orally administered vitamin A (10,000 IU)
Outcomes Stillbirths, HIV infection in child, preterm delivery, low birthweight, postpartum CD4
levels
Notes All women received oral vitamin A (100,000 IU) at 6 weeks postpartum, as per policy
of the Malawi Ministry of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors determined treatment as-
signment by use of a computer random-
number generator
Allocation concealment (selection bias) Low risk Treatment assignment was concealed by
pre-packing study supplements in sequen-
tially numbered series assigned to study
identification numbers. Mothers were as-
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Kumwenda 2002 (Continued)
signed an original study identification
number at enrolment and were given the
next sequentially numbered opaque bottle
with supplements
Blinding (performance bias and detection
bias)
All outcomes
Low risk Supplements containing vitamin A, iron,
and folate were identical in appearance to
the supplements containing iron and folate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nine per cent of women were lost to fol-
low-up and we do not believe that this was
related to the outcome. We do not believe
this introduced bias
Selective reporting (reporting bias) Low risk The trial authors reported on all outcomes
specified in the goals of the study articles
Other bias Low risk We do not believe that other biases were in-
troduced that could have affected the study
findings
Abbreviations: ART: antiretroviral therapy; MTCT: mother-to-child transmission; RCT: randomized controlled trial.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Duggan 2012 The intervention consisted of multiple multivitamins (not vitamin A) and the participants were children born to
HIV-positive women (rather than the women themselves)
Friis 2004 The intervention consisted of multiple multivitamins and not vitamin A
Locks 2017 The intervention consisted of multiple multivitamins (not vitamin A) and the participants were children born to
HIV-positive women (rather than the women themselves)
Olofin 2016 The intervention consisted of multiple multivitamins (not vitamin A) and the participants were children born to
HIV-positive women (rather than the women themselves)
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin A supplementation versus no vitamin A supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HIV infection status of the child 5 4428 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.91, 1.26]
1.1 Antepartum
supplementation
2 650 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.67, 1.09]
1.2 Postpartum
supplementation
1 2248 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.98, 1.27]
1.3 Antepartum and
postpartum supplementation
2 1530 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.86, 1.59]
2 Mean birthweight 3 2181 Mean Difference (IV, Random, 95% CI) 34.12 [-12.79, 81.
02]
3 Low birthweight 3 1819 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.63, 0.97]
4 Child death by two years of age 3 3883 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.92, 1.22]
5 Preterm delivery 2 1577 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.52, 1.37]
6 Stillbirth 3 2335 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.72, 1.77]
7 Maternal death 2 1267 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.35, 1.43]
8 Postpartum CD4 count 1 511 Mean Difference (IV, Random, 95% CI) -13.0 [-60.46, 34.
46]
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Analysis 1.1. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 1
HIV infection status of the child.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 1 HIV infection status of the child
Study or subgroup Vitamin A No vitamin A Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Antepartum supplementation
Chikobvu 2000 14/73 18/85 5.7 % 0.91 [ 0.48, 1.69 ]
Kumwenda 2002 67/242 82/250 19.1 % 0.84 [ 0.64, 1.11 ]
Subtotal (95% CI) 315 335 24.9 % 0.85 [ 0.67, 1.09 ]
Total events: 81 (Vitamin A), 100 (No vitamin A)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Postpartum supplementation
Humphrey 2006 346/1126 310/1122 32.7 % 1.11 [ 0.98, 1.27 ]
Subtotal (95% CI) 1126 1122 32.7 % 1.11 [ 0.98, 1.27 ]
Total events: 346 (Vitamin A), 310 (No vitamin A)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
3 Antepartum and postpartum supplementation
Coutsoudis 1999 70/319 70/313 17.5 % 0.98 [ 0.73, 1.31 ]
Fawzi 2002 155/453 113/445 24.9 % 1.35 [ 1.10, 1.65 ]
Subtotal (95% CI) 772 758 42.4 % 1.17 [ 0.86, 1.59 ]
Total events: 225 (Vitamin A), 183 (No vitamin A)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.05, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 2213 2215 100.0 % 1.07 [ 0.91, 1.26 ]
Total events: 652 (Vitamin A), 593 (No vitamin A)
Heterogeneity: Tau2 = 0.02; Chi2 = 8.48, df = 4 (P = 0.08); I2 =53%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 3.86, df = 2 (P = 0.15), I2 =48%
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Analysis 1.2. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 2
Mean birthweight.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 2 Mean birthweight
Study or subgroup Vitamin A No vitamin A
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Coutsoudis 1999 346 3085 (562) 343 3069 (573) 28.4 % 16.00 [ -68.76, 100.76 ]
Kumwenda 2002 285 2895 (523) 309 2805 (563) 26.9 % 90.00 [ 2.67, 177.33 ]
Fawzi 2002 453 3005 (507) 445 2993 (504) 44.7 % 12.00 [ -54.13, 78.13 ]
Total (95% CI) 1084 1097 100.0 % 34.12 [ -12.79, 81.02 ]
Heterogeneity: Tau2 = 144.06; Chi2 = 2.18, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
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Analysis 1.3. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 3
Low birthweight.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 3 Low birthweight
Study or subgroup Vitamin A No vitamin A Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Coutsoudis 1999 42/346 48/343 32.0 % 0.87 [ 0.59, 1.28 ]
Fawzi 2002 39/269 46/267 31.1 % 0.84 [ 0.57, 1.24 ]
Kumwenda 2002 40/285 65/309 36.9 % 0.67 [ 0.47, 0.96 ]
Total (95% CI) 900 919 100.0 % 0.78 [ 0.63, 0.97 ]
Total events: 121 (Vitamin A), 159 (No vitamin A)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.4. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 4
Child death by two years of age.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 4 Child death by two years of age
Study or subgroup Vitamin A No vitamin A Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fawzi 2002 163/527 159/514 60.6 % 1.00 [ 0.83, 1.20 ]
Kumwenda 2002 69/285 68/309 23.2 % 1.10 [ 0.82, 1.48 ]
Humphrey 2006 67/1126 53/1122 16.2 % 1.26 [ 0.89, 1.79 ]
Total (95% CI) 1938 1945 100.0 % 1.06 [ 0.92, 1.22 ]
Total events: 299 (Vitamin A), 280 (No vitamin A)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.5. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 5
Preterm delivery.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 5 Preterm delivery
Study or subgroup Vitamin A No vitamin A Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Coutsoudis 1999 39/346 60/343 45.7 % 0.64 [ 0.44, 0.94 ]
Fawzi 2002 105/449 97/439 54.3 % 1.06 [ 0.83, 1.35 ]
Total (95% CI) 795 782 100.0 % 0.84 [ 0.52, 1.37 ]
Total events: 144 (Vitamin A), 157 (No vitamin A)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.77, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 6
Stillbirth.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 6 Stillbirth
Study or subgroup Vitamin A No vitamin A Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Coutsoudis 1999 6/341 4/330 13.0 % 1.45 [ 0.41, 5.10 ]
Kumwenda 2002 8/306 6/317 18.7 % 1.38 [ 0.48, 3.93 ]
Fawzi 2002 25/527 24/514 68.4 % 1.02 [ 0.59, 1.76 ]
Total (95% CI) 1174 1161 100.0 % 1.13 [ 0.72, 1.77 ]
Total events: 39 (Vitamin A), 34 (No vitamin A)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 7
Maternal death.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 7 Maternal death
Study or subgroup Vitamin A No vitamin A Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Coutsoudis 1999 1/368 2/360 8.5 % 0.49 [ 0.04, 5.37 ]
Fawzi 2002 12/272 16/267 91.5 % 0.74 [ 0.36, 1.53 ]
Total (95% CI) 640 627 100.0 % 0.71 [ 0.35, 1.43 ]
Total events: 13 (Vitamin A), 18 (No vitamin A)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Vitamin A supplementation versus no vitamin A supplementation, Outcome 8
Postpartum CD4 count.
Review: Vitamin A supplements for reducing mother-to-child HIV transmission
Comparison: 1 Vitamin A supplementation versus no vitamin A supplementation
Outcome: 8 Postpartum CD4 count
Study or subgroup Vitamin A No vitamin A
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fawzi 2002 257 496 (294) 254 509 (252) 100.0 % -13.00 [ -60.46, 34.46 ]
Total (95% CI) 257 254 100.0 % -13.00 [ -60.46, 34.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Search strategy used on 25 August 2017
Search set CENTRAL PubMed Embase WHO ICTRP ClinicalTrials.gov
#1 MeSH descrip-
tor: [HIV Infections]
explode all trees
Search ((HIV In-
fections[MeSH]
OR HIV[MeSH]
OR hiv[tiab] OR
hiv-1*[tiab] OR
hiv-2*[tiab] OR
hiv1[tiab] OR
hiv2[tiab] OR hiv
infect*[tiab] OR
human immunodefi-
ciency virus[tiab] OR
human immunede-
ficiency virus[tiab]
OR human immuno-
deficiency virus[tiab]
OR human im-
mune-deficiency
virus[tiab] OR ((hu-
man immun*[tiab])
AND (deficiency
virus[tiab])) OR
acquired immun-
odeficiency syn-
drome[tiab] OR
acquired immuned-
eficiency syn-
drome[tiab] OR
acquired immuno-
deficiency syn-
drome[tiab] OR
acquired immune-
deficiency syn-
drome[tiab] OR ((ac-
quired immun*[tiab])
AND (deficiency
syndrome[tiab]))
OR “sexually trans-
mitted diseases, Vi-
ral”[MeSH:NoExp]))
’human immunode-
ficiency virus infec-
tion’/exp OR ’human
im-
munodeficiency virus
infection’/de OR
’human immunodefi-
ciency virus infection’
OR ’human immun-
odeficiency virus’/exp
OR ’human immun-
odeficiency virus’/de
OR ’human immun-
odeficiency virus’ OR
’human immunodefi-
ciency virus:ab,ti’ OR
hiv:ab,ti OR ’hiv-1’:
ab,
ti OR ’hiv-2’:ab,ti OR
’human immunodefi-
ciency virus’:ab,ti OR
’human immunedefi-
ciency virus’:ab,ti OR
’human immune-
deficiency virus’:ab,ti
OR ’human immuno-
deficiency virus’:ab,ti
OR ’ac-
quired immunodefi-
ciency syndrome’:ab,
ti OR ’acquired im-
muno-deficiency syn-
drome’:ab,ti OR ’ac-
quired immune-defi-
ciency syndrome’:ab,
ti OR ’acquired im-
munedeficiency syn-
drome’:ab,ti
hiv AND vitamin A
OR hiv AND retinol
OR hiv AND retinoic
OR hiv AND mi-
cronutrients OR hiv
AND carotene
HIV and “VITAMIN
A” | Interventional
Studies | Studies re-
ceived from 05/20/
2016 to 08/25/2017
#2 MeSH descrip-
tor: [HIV] explode all
trees
Search (randomized
controlled trial [pt]
OR controlled clini-
cal trial [pt] OR ran-
domized [tiab] OR
placebo
’random-
ized controlled trial’/
de OR ’randomized
controlled trial’ OR
random*:ab,ti OR
trial:ti OR allocat*:
- -
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Table 1. Search strategy used on 25 August 2017 (Continued)
[tiab] OR “clinical tri-
als as topic”[mesh: no-
exp] OR randomly
[tiab] OR trial [tiab])
NOT (animals [mh]
NOT humans [mh])
ab,ti OR factorial*:ab,
ti OR placebo*:ab,ti
OR assign*:ab,ti OR
volunteer*:ab,ti OR
’crossover procedure’/
de OR ’crossover pro-
cedure’ OR ’double-
blind pro-
cedure’/de OR ’dou-
ble-blind procedure’
OR ’single-blind pro-
cedure’/de OR ’sin-
gle-blind procedure’
OR ((doubl* NEAR/
3 blind*):ab,ti) OR
(singl*:
ab,ti AND blind*:ab,
ti) OR crossover*:ab,
ti OR cross+over*:ab,
ti OR ((cross NEXT/
1 over*):ab,ti)
#3 hiv or hiv-1* or hiv-
2* or hiv1 or hiv2 or
(hiv near infect*) or
(human immunodefi-
ciency
virus) or (human im-
munedeficiency virus)
or (human immune-
deficiency virus) or
(human immuno-de-
ficiency virus) or (hu-
man immune defi-
ciency virus) or (hu-
man immuno defi-
ciency virus) or (ac-
quired immunodefi-
ciency syndrome) or
(acquired immunede-
ficiency syndrome) or
(acquired immuno-
deficiency syndrome)
or (acquired immune-
deficiency syndrome)
or (acquired immun*
deficiency syndrome)
(Word variations have
been searched)
Search (infectious dis-
ease transmission, ver-
tical[mh] OR verti-
cal transmission[tiab]
OR
vertical infect*[tiab]
OR infection trans-
mission[tiab]
OR mother-to-child
transmission[tiab]
OR MTCT[tiab])
’animal’/de OR ’an-
imal experiment’/de
OR ’invertebrate’/de
OR ’animal tissue’/de
OR ’animal cell’/de
OR ’nonhuman’/de
- -
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Table 1. Search strategy used on 25 August 2017 (Continued)
#4 MeSH de-
scriptor: [Lymphoma,
AIDS-Related] this
term only
Search (vita-
min A[mh] OR vita-
min*[tiab] OR
caroten*[tiab]
OR retinol[tiab] OR
retinoic[tiab] OR mi-
cronutrient*[tiab])
’human’/de OR ’nor-
mal human’/de OR
’human cell’/de
- -
#5 MeSH descrip-
tor: [Sexually Trans-
mitted Diseases, Vi-
ral] this term only
Search (#1 AND #2
AND #3 AND #4)
#3 AND #4 - -
#6 #1 or #2 or #3 or #4
or #5
Search (((#1 AND #
2 AND #3 AND
#4))) AND (“2016/
05/20”[Date - Pub-
lication] : “2017/08/
25”[Date - Publica-
tion])
#3 NOT #5 - -
#7 [mh “infectious dis-
ease transmission, ver-
tical”]
or “vertical transmis-
sion”:ti,ab,kw or ver-
tical next infect*:ti,ab,
kw or “infec-
tion transmission”:ti,
ab,kw or “mother-to-
child transmission”:ti,
ab,kw or MTCT:ti,
ab,kw
(Word variations have
been searched)
- #2 NOT #6 - -
#8 [mh “vita-
min A”] or vitamin*:
ti,ab,kw or caroten*:
ti,ab,kw or retinol:ti,
ab,kw or retinoic:ti,
ab,kw or micronutri-
ent*:ti,ab,kw (Word
variations have been
searched)
- ’vertical trans-
mission’/de OR ’verti-
cal transmission’:ab,ti
OR ’infectious disease
transmission’:ab,ti
OR ’mother+to+child
transmission’:ab,ti
OR mtct:ab,ti
- -
#9 #6 and #7 and #8 - caroten*:
ab,ti OR retinoic:ab,
ti OR ’retinol’/de OR
- -
37Vitamin A supplements for reducing mother-to-child HIV transmission (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Search strategy used on 25 August 2017 (Continued)
retinol:ab,ti OR vi-
tamin*:ab,ti OR ’vi-
tamin a’/de OR mi-
cronutrient*:ab,ti
#10 #6 and #7 and #8
Publication Year from
2016 to 2017
- #1 AND #7 AND #8
AND #9
- -
#11 - - #1 AND #7 AND #8
AND#9 AND [20-5-
2016]/sd NOT [25-
8-2017]/sd
- -
Table 2. Search strategy used on 20 May 2016
Search set CENTRAL PubMed Embase
#1 HIV Infections HIV Infections OR HIV OR hiv OR
hiv-1* OR hiv-2* OR hiv1 OR hiv2
OR hiv infect* OR human immunod-
eficiency virus OR human immuned-
eficiency virus OR human immuno-
deficiency virus OR human immune-
deficiency virus OR (human immun*
AND deficiency virus) OR acquired
immunodeficiency syndrome OR ac-
quired immunedeficiency syndrome
OR acquired immuno-deficiency syn-
drome OR acquired immune-defi-
ciency syndrome OR (acquired im-
mun* AND deficiency syndrome) OR
“sexually transmitted diseases, Viral”
human immunodeficiency virus infec-
tion OR human immunodeficiency
virus infection OR human immunod-
eficiency virus infection OR human
immunodeficiency virus OR human
immunodeficiency virus OR human
immunodeficiency virus OR human
immunodeficiency virus OR hiv OR
hiv-1ORhiv-2ORhuman immunod-
eficiency virus OR human immuned-
eficiency virus OR human immune-
deficiency virus OR human immuno-
deficiency virus OR acquired immun-
odeficiency syndrome OR acquired
immuno-deficiency syndrome OR ac-
quired immune-deficiency syndrome
OR acquired immunedeficiency syn-
drome
#2 HIV randomized controlled trial OR con-
trolled clinical trial OR randomized
OR placebo OR “clinical trials as
topic” OR randomly OR trial) NOT
(animals NOT humans)
randomized controlled trial OR ran-
domized controlled trial OR random*
ORtrialORallocat*OR factorial*OR
placebo* OR assign* OR volunteer*
OR crossover procedure OR crossover
procedure OR double-blind proce-
dure OR double-blind procedure OR
single-blind procedure OR single-
blind procedure OR doubl* NEAR/
3 blind* OR singl* AND blind* OR
crossover* OR cross+over* OR cross
NEXT/1 over*
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Table 2. Search strategy used on 20 May 2016 (Continued)
#3 hiv or hiv-1* or hiv-2* or hiv1 or hiv2
or hiv near infect* or human immun-
odeficiency virus or human immuned-
eficiency virus or human immune-de-
ficiency virus or human immuno-de-
ficiency virus or human immune de-
ficiency virus or human immuno de-
ficiency virus or acquired immunod-
eficiency syndrome or acquired im-
munedeficiency syndrome or acquired
immuno-deficiency syndrome or ac-
quired immune-deficiency syndrome
or acquired immun* deficiency syn-
drome
infectious disease transmission, verti-
cal OR vertical transmission OR verti-
cal infect* OR infection transmission
ORmother-to-child transmission OR
MTCT
animal OR animal experiment OR in-
vertebrate OR animal tissue OR ani-
mal cell OR nonhuman
#4 Lymphoma, AIDS-Related vitamin A OR vitamin* OR caroten*
OR retinol OR retinoic OR micronu-
trient*
human OR normal human OR hu-
man cell
#5 Sexually Transmitted Diseases, Viral 1-4/AND #3 AND #4
#6 1-5/OR 5 AND (2010/06/01 NOT 2016/05/
20)
#3 NOT #5
#7 infectious disease transmission, verti-
cal or vertical transmission or verti-
cal next infect* or infection transmis-
sion or mother-to-child transmission
or MTCT
- #2 NOT #6
#8 vitamin A or vitamin* or caroten* or
retinol or retinoic or micronutrient*
- vertical transmission OR vertical
transmission OR infectious disease
transmission OR mother+to+child
transmission OR mtct
#9 6-8/AND - caroten* OR retinoic OR retinol OR
retinolORvitamin*ORvitamin aOR
micronutrient*
#10 Limit 9 to publication date 2010-2016 - #1 AND #7 AND #8 AND #9
#11 - - #10 AND (2010/06/01 NOT 2016/
05/20)
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Table 3. Search strategy used in June 2010
Search set CENTRAL PubMed Embase
#1 MeSH descriptor HIV Infections ex-
plode all trees
Search HIV
Infections[MeSH] OR HIV[MeSH]
OR hiv[tw] OR hiv-1*[tw] OR hiv-
2*[tw] OR hiv1[tw] OR hiv2[tw] OR
hiv infect*[tw] OR human immun-
odeficiency virus[tw] OR human im-
munedeficiency virus[tw] OR human
immuno-deficiency virus[tw] OR hu-
man immune-deficiency virus[tw] OR
((human immun*) AND (deficiency
virus[tw])) OR acquired immunodefi-
ciency syndrome[tw]OR acquired im-
munedeficiency
syndrome[tw] OR acquired immuno-
deficiency syndrome[tw] OR acquired
immune-deficiency syndrome[tw]OR
((acquired immun*) AND (deficiency
syndrome[tw])) OR “sexually trans-
mitted diseases, viral”[MESH:NoExp]
’human immunodeficiency virus in-
fection’/exp OR ’human immunode-
ficiency virus infection’/de OR ’hu-
man immunodeficiency virus infec-
tion’ OR ’human immunodeficiency
virus’/exp OR ’human immunode-
ficiency virus’/de OR ’human im-
munodeficiency virus’OR hiv:ti OR
hiv:ab OR ’hiv-1’:ti OR ’hiv-1’:
ab OR ’hiv-2’:ti OR ’hiv-2’:ab OR
’human immunodeficiency virus’:ti
OR ’human immunodeficiency virus’:
ab OR ’human immuno-deficiency
virus’:ti OR ’human immuno-defi-
ciency virus’:ab OR ’human im-
munedeficiency virus’:ti OR ’human
immunedeficiency virus’:ab OR ’hu-
man immune-deficiency virus’:ti OR
’human immune-deficiency virus’:ab
OR ’acquired immune-deficiency syn-
drome’:ti OR ’acquired immune-defi-
ciency syndrome’:abOR ’acquired im-
munedeficiency syndrome’:ti OR ’ac-
quired immunedeficiency syndrome’:
ab OR ’acquired immunodeficiency
syndrome’:ti OR ’acquired immun-
odeficiency syndrome’:ab OR ’ac-
quired immuno-deficiency syndrome’:
ti OR ’acquired immuno-deficiency
syndrome’:ab
#2 MeSHdescriptorHIV explode all trees Search (randomised controlled trial
[pt] OR controlled clinical trial [pt]
OR randomised [tiab] OR placebo
[tiab] OR drug therapy [sh] OR ran-
domly [tiab]OR trial [tiab]ORgroups
[tiab]) NOT (animals [mh] NOT hu-
mans [mh])
random*:ti OR random*:ab OR fac-
torial*:ti OR factorial*:ab OR cross?
over*:
ti OR cross?over*:ab OR crossover*:
ti OR crossover*:ab OR placebo*:ti
OR placebo*:ab OR (doubl*:ti AND
blind*:ti)OR (doubl*:abANDblind*:
ab) OR (singl*:ti AND blind*:ti) OR
(singl*:ab AND blind*:ab) OR as-
sign*:ti OR assign*:ab OR allocat*:
ti OR allocat*:ab OR volunteer*:ti
OR volunteer*:ab OR ’crossover pro-
cedure’/exp OR ’crossover procedure’/
de OR ’crossover procedure’OR ’dou-
ble-blind procedure’/exp OR ’double-
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Table 3. Search strategy used in June 2010 (Continued)
blind procedure’/de OR ’double-blind
procedure’ OR ’single-blind proce-
dure’/expOR ’single-blindprocedure’/
de OR ’single-blind procedure’ OR
’randomised controlled trial’/exp OR
’randomised controlled trial’/de OR
’randomised controlled trial’
#3 hiv OR hiv-1* OR hiv-2* OR hiv1
OR hiv2 OR HIV INFECT* OR
HUMAN IMMUNODEFICIENCY
VIRUS OR HUMAN IMMUNED-
EFICIENCY VIRUS OR
HUMAN IMMUNE-DEFICIENCY
VIRUS OR HUMAN IMMUNO-
DEFICIENCYVIRUSORHUMAN
IMMUN* DEFICIENCY VIRUS
OR ACQUIRED IMMUNODEFI-
CIENCY SYNDROME OR AC-
QUIRED IMMUNEDEFICIENCY
SYNDROME OR ACQUIRED IM-
MUNO-DE-
FICIENCY SYNDROME OR AC-
QUIRED IMMUNE-DEFICIENCY
SYNDROME OR ACQUIRED IM-
MUN*DEFICIENCYSYNDROME
Search mother-to-child-transmission
OR MTCT OR infectious disease
transmission, vertical
’mother-to-child transmission’ OR
’mother to child transmission’ OR
mtctOR ’vertical transmission’/de OR
’vertical transmission’
#4 MeSH descriptor Lymphoma, AIDS-
Related, this term only
Search caroten* OR retinoic OR
retinol OR vitamin* OR vitamin A
OR micronutrient*
caroten* OR retinoicOR ’retinol’/de
OR retinolOR vitamin*OR ’vitamin
a’/de OR ’vitamin a’OR micronutri-
ent*
#5 MeSH descriptor Sexually Transmit-
ted Diseases, Viral, this term only
Search #1 AND #2 AND #3 AND #4
Limits: Publication Date from 2007/
01/01 to 2010/06/08
#1 AND #2AND #3AND #4
#6 (#1 OR #2 OR #3 OR #4 OR #5) - #1 AND #2AND #3AND #
4AND [humans]/lim AND [embase]/
lim AND [1-1-2007]/sd NOT [8-6-
2010]/sd
#7 mother-to-child-transmission OR
MTCT
- -
#8 MeSH descriptor Infectious Disease
Transmission, Vertical, this term only
- -
#9 (#7 OR #8) - -
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Table 3. Search strategy used in June 2010 (Continued)
#10 caroten*ORretinoicORvitamin*OR
vitamin A OR micronutrient*
- -
#11 (#6 AND #9 AND #10) - -
#12 (#6 AND #9 AND #10), from 2007
to 2010
- -
Table 4. Search strategy used in February 2008
Search set PubMed Embase AIDSearch GATEWAY
#1 Search
HIV Infections[MeSH] OR
HIV[MeSH] OR hiv[tw]
OR hiv-1*[tw] OR hiv-
2*[tw] OR hiv1[tw] OR
hiv2[tw] OR hiv infect*[tw]
OR human immunodefi-
ciency virus[tw] OR human
immunedeficiency
virus[tw] OR human im-
muno-deficiency virus[tw]
OR human immune-defi-
ciency virus[tw] OR ((hu-
man immun*)
AND (deficiency virus[tw])
) OR acquired immunode-
ficiency syndrome[tw] OR
acquired immunedeficiency
syndrome[tw] OR acquired
immuno-deficiency
syndrome[tw] OR acquired
immune-deficiency syn-
drome[tw] OR ((acquired
immun*) AND (deficiency
syndrome[tw])) OR “sexu-
ally transmitted diseases, vi-
ral”[MH]
((’human
immunodeficiency virus in-
fection’/expOR ’human im-
munodeficiency virus infec-
tion’) OR (’human immun-
odeficiency virus infection’/
exp OR ’human immun-
odeficiency virus infection’)
) OR (((’human immun-
odeficiency virus’/exp OR
’human immunodeficiency
virus’) OR (’human im-
munodeficiency virus’/exp
OR ’human immunodefi-
ciency virus’))) OR (((’b
cell lymphoma’/exp OR ’b
cell lymphoma’) OR (’b
cell lymphoma’/exp OR ’b
cell lymphoma’))) OR (hiv:
ti OR hiv:ab) OR (’hiv-1’:
ti OR ’hiv-1’:ab) OR (’hiv-
2’:ti OR ’hiv-2’:ab) OR
(’human immunodeficiency
virus’:ti OR
’human immunodeficiency
virus’:ab) OR (’human im-
munedeficiency virus’:tiOR
’human immunedeficiency
virus’:ab) OR (’human
(HIV INFECTIONS) OR
HIV OR HIV OR HIV-1*
OR HIV-2* OR HIV1 OR
HIV2OR (HIV INFECT*)
OR (HUMAN IMMUN-
OD-
EFICIENCY VIRUS) OR
(HUMAN IMMUNEDE-
FICIENCY VIRUS) OR
(HUMAN IMMUNO-
DE-
FICIENCY VIRUS) OR
(HUMAN IMMUNE-DE-
FICIENCY VIRUS) OR (
(HUMAN
IMMUN*) AND (DEFI-
CIENCY VIRUS)
) OR (ACQUIRED IM-
MUNODEFICIENCY
SYNDROME) OR (AC-
QUIRED IMMUNEDE-
FICIENCY SYNDROME)
OR (AC-
QUIRED IMMUNO-DE-
FICIENCY SYNDROME)
OR (AC-
QUIRED IMMUNE-DE-
FICIENCY SYNDROME)
OR ((ACQUIRED
IMMUN*) AND (DEFI-
CIENCY SYNDROME))
OR (SEXUALLY TRANS-
MITTED DISEASES, VI-
RAL)
Search: (HIV
Infections[MeSH] OR
HIV[MeSH] OR hiv[tw]
OR hiv-1*[tw] OR hiv-
2*[tw] OR hiv1[tw] OR
hiv2[tw] OR hiv infect*[tw]
OR human immunodefi-
ciency virus[tw] OR human
immunedeficiency
virus[tw] OR human im-
muno-deficiency virus[tw]
OR human immune-defi-
ciency virus[tw] OR ((hu-
man immun*) AND (defi-
ciency virus[tw])) OR ac-
quired immun-
odeficiency syndrome[tw])
AND (acquired immuned-
eficiency syndrome[tw] OR
ac-
quired immuno-deficiency
syndrome[tw] OR acquired
immune-deficiency syn-
drome[tw] OR ((acquired
immun*) AND (deficiency
syndrome[tw])) OR “sexu-
ally transmitted diseases, vi-
ral”[MH])
42Vitamin A supplements for reducing mother-to-child HIV transmission (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 4. Search strategy used in February 2008 (Continued)
#2 Search randomised
controlled trial [pt]ORcon-
trolled clinical trial [pt] OR
randomised controlled tri-
als [mh] OR random al-
location [mh] OR double-
blind method [mh] OR sin-
gle-blind method [mh] OR
clinical trial [pt] OR clini-
cal trials [mh] OR (“clinical
trial” [tw]) OR ((singl* [tw]
OR doubl* [tw] OR trebl*
[tw] OR tripl* [tw]) AND
(mask* [tw]ORblind* [tw])
) OR ( placebos [mh] OR
placebo* [tw] OR random*
[tw] OR research design
[mh:noexp] OR (compar-
ative study) OR (compar-
ative studies) OR (evalua-
tion studies) OR follow-up
studies [mh] OR prospec-
tive studies [mh] OR con-
trol* [tw] OR prospectiv*
[tw] OR volunteer* [tw])
NOT (animals [mh] NOT
human [mh])
(random*:ti OR random*:
ab) OR (factorial*:ti OR
factorial*:ab) OR (cross?
over*:ti OR cross?over:ab
OR crossover*:
ti OR crossover*:ab) OR
(placebo*:ti OR placebo*:
ab) OR (((doubl*:ti AND
blind*:ti) OR (doubl*:ab
AND blind*:ab))) OR (
((singl*:ti AND blind*:ti)
OR (singl*:ab AND blind*:
ab))) OR (assign*:ti OR as-
sign*:ab) OR (volunteer*:
ti OR volunteer*:ab) OR (
(((’crossover procedure’/exp
OR ’crossover procedure’)
OR (’crossover procedure’/
exp OR ’crossover proce-
dure’)) OR ((’crossover pro-
cedure’/exp OR ’crossover
procedure’) OR (’crossover
procedure’/exp
OR ’crossover procedure’)))
) OR (
(((’double-blind procedure’/
exp OR ’double-blind pro-
cedure’) OR (’double-blind
procedure’/exp OR ’dou-
ble-blind procedure’)) OR
((’double-blind procedure’/
exp OR ’double-blind pro-
cedure’) OR (’double-blind
procedure’/exp OR ’double-
blind procedure’)))) OR (
(((’single-blind procedure’/
exp OR ’single-blind pro-
cedure’) OR (’single-blind
procedure’/exp OR ’single-
blind procedure’)) OR (
(’single-blind procedure’/
exp OR ’single-blind pro-
cedure’) OR (’single-blind
procedure’/exp OR ’single-
blind procedure’))
)) OR ((((’randomised con-
trolled trial’/exp OR ’ran-
((RANDOMIZED CON-
TROLLED TRIAL) OR
(CONTROLLED CLINI-
CAL TRIAL) OR (RAN-
DOMIZED
CONTROLLED TRIALS)
OR (RANDOM ALLO-
CATION) OR (DOUBLE-
BLIND METHOD) OR
(SINGLE-BLIND
METHOD) OR (CLINI-
CAL TRIAL) OR (CLINI-
CAL
TRIALS) OR (“CLINICAL
TRIAL”)OR ((SINGL*OR
DOUBL*ORTREBL* OR
TRIPL* AND (MASK*OR
BLIND* )) OR PLACE-
BOS
OR PLACEBO* OR RAN-
DOM* OR (COMPARA-
TIVESTUDY)OR(EVAL-
UATION STUDIES) OR
(FOLLOW-UP STUDIES)
OR
(PROSPECTIVE STUD-
IES) OR CONTROL* OR
PROSPECTIV* OR VOL-
UNTEER*)) NOT (ANI-
MALS NOT HUMAN )
Search: (randomised con-
trolled trial [pt] OR con-
trolled clinical trial [pt] OR
randomised controlled tri-
als [mh] OR random al-
location [mh] OR double-
blind method [mh] OR sin-
gle-blind method [mh] OR
clinical trial [pt] OR clini-
cal trials [mh] OR (“clinical
trial” [tw]) OR ((singl* [tw]
OR doubl* [tw] OR trebl*
[tw] OR tripl* [tw]) AND
(mask* [tw]ORblind* [tw])
)) OR (( placebos [mh]
OR placebo* [tw] OR ran-
dom* [tw] OR research de-
sign [mh:noexp] OR (com-
parative study) OR (com-
parative studies) OR (evalu-
ation studies) OR follow-up
studies [mh] OR prospec-
tive studies [mh] OR con-
trol* [tw] OR prospectiv*
[tw] OR volunteer* [tw])
NOT (animals [mh] NOT
human [mh]))
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Table 4. Search strategy used in February 2008 (Continued)
domised controlled trial’)
OR (’randomised controlled
trial’/exp OR ’randomised
controlled trial’)) OR ((’ran-
domised controlled trial’/
exp
OR ’randomised controlled
trial’)OR (’randomised con-
trolled trial’/exp OR ’ran-
domised controlled trial’))))
OR (allocat*:ti OR allocat*:
ab) AND [2003-2008]/py
#3 Search (DISEASE TRANS-
MIS-
SION, VERTICAL) OR
MTCT OR (MOTHER-
TO-CHILD TRANSMIS-
SION)
’mother-to-child transmis-
sion’ OR mtct OR ’vertical
disease transmission’ AND
[2003-2008]/py
(MOTHER-
TO-CHILD TRANSMIS-
SION) OR MTCT
OR (VERTICALDISEASE
TRANSMISSION)
Search: (DISEASE
TRANSMIS-
SION, VERTICAL) OR
MTCT OR (MOTHER-
TO-CHILD TRANSMIS-
SION)
#4 Search CAROTEN* OR
RETINOIC
OR RETINOL OR VI-
TAMIN* ORMICRONU-
TRIENT*
caroten* OR retinoic OR
(’retinol’/exp OR ’retinol’)
OR vitamin* OR micronu-
trient* AND [2003-2008]/
py
CAROTEN* OR
RETINOIC
OR RETINOL OR VI-
TAMIN* ORMICRONU-
TRIENT*
Search: CAROTEN* OR
RETINOIC
OR RETINOL OR VI-
TAMIN* ORMICRONU-
TRIENT*
#5 Search PREG-
NANTOR PREGNANCY
OR ANTEPARTUM OR
PRENATAL OR ANTE-
PARTUM OR PRE-NA-
TAL OR PREPART*
pregnant OR (’pregnancy’/
exp OR ’pregnancy’) OR
antepartum OR (’ante par-
tum’) OR antenatal OR
(’ante natal’) OR prena-
tal OR (’pre natal’) AND
[2003-2008]/py
PREGNANT OR PREG-
NANCY OR AN-
TEPARTUM OR (ANTE-
PARTUM) OR ANTENA-
TAL OR (ANTE-NATAL)
ORPRENATALOR (PRE-
NATAL)
Search: PREG-
NANTOR PREGNANCY
OR ANTEPARTUM OR
PRENATAL OR ANTE-
PARTUM OR PRE-NA-
TAL OR PREPART*
#6 Search #1 AND #2 AND #
3 AND #4 AND #5 Limits:
Publication Date from 2003
to 2008
#1 AND #2 AND #3 AND
#4 AND #5
#1 AND #2 AND #3 AND
#4 AND #5
#1 and #2 and #3 and #4
and #5 Limit: 2003:2008
Table 5. Optimal information size calculation
Outcome Assumed risk Source Clinically important relative im-
provement
Sample size required
HIV infection in child 27/100 Analysis 1.1 25% 1236
Mean birthweight 2964 Analysis 1.2 25% 6178
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Table 5. Optimal information size calculation (Continued)
Low birthweight 17/100 Analysis 1.3 25% 2194
Still birth 3/100 Analysis 1.4 25% 14,264
Preterm birth 20/100 Analysis 1.5 25% 1806
Child death 14/100 Analysis 1.6 25% 2748
Maternal death 3/100 Analysis 1.7 25% 14,264
We based the sample size calculations: 2-sided tests, with ratio of 1:1, power of 0.8 and confidence level of 0.05.
We performed the sample size calculations using http://www.sealedenvelope.com/power/binary-superiority/
WH A T ’ S N E W
Last assessed as up-to-date: 25 August 2017.
Date Event Description
7 September 2017 New search has been performed One new trial met the inclusion criteria of this review
update. We excluded one trial that was included in the
previous edition of the review, Wiysonge 2011, from
this review update because it did not meet our inclu-
sion criteria, and we re-extracted birthweight data. We
amended the number of child-related andmaternal sec-
ondary outcomes. In addition, there were changes to
the review author team
7 September 2017 New citation required but conclusions have not
changed
This is an update to a review published in 2011.
H I S T O R Y
Protocol first published: Issue 2, 2002
Review first published: Issue 2, 1995
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Date Event Description
18 January 2011 Amended External source of support added.
7 September 2010 New citation required but conclusions have not
changed
Review expanded to include postpartum supplementa-
tion; SOF table added
7 September 2010 New search has been performed Updated, with GRADE Summary of Findings table.
14 May 2008 Amended Converted to new review format.
14 May 2008 New search has been performed Update of review.
11 January 2008 New citation required and conclusions have changed Substantive amendment
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External sources
• Effective Health Care Research Consortium, UK.
Grant: 5242
• National Research Foundation of South Africa, South Africa.
Grant: 108571
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between 2011 review and this review update
Authorship
The 2011 review had five authors (Wiysonge CS, Shey MS, Kongnyuy EJ, Sterne JA, and Brocklehurst P), but the current update has
four authors (Wiysonge CS, Ndze VN, Kongnyuy EJ, and Shey MS).
Primary outcome
There are no differences between the two versions of the review, as both have an identical primary outcome (HIV infection status of
the child).
Secondary outcomes
The 2011 review had 12 secondary outcomes linked to the child (infant death, stillbirth, neonatal sepsis, neonatal admission to neonatal
unit, death by 24 months of age, side effects in the child, preterm delivery, very preterm delivery, birth weight, low birth weight, very
low birthweight, and long-term side effects in survivors) and five maternal secondary outcomes (maternal death, postpartum infection,
side effects in the mother, cost of the intervention, and acceptability of the intervention). The current update has five child-related
secondary outcomes (mean birthweight, low birthweight, child death by two years of age, preterm delivery, and stillbirth) and two
secondary outcomes linked to the mother (maternal death and postpartum CD4 count).
Methods
In Wiysonge 2011, we used a fixed-effect method as our default method for meta-analysis, and only used a random-effects model when
there was substantial statistical heterogeneity (P < 0.1). However, due to clinical heterogeneity, we used the random-effects method for
all meta-analyses in this review update.
Included studies
We included five studies in the 2011 review (Coutsoudis 1999; Fawzi 2002; Kumwenda 2002; Friis 2004; Humphrey 2006), and five
reviews in the current update (Coutsoudis 1999; Chikobvu 2000; Fawzi 2002; Kumwenda 2002; Humphrey 2006). We included Friis
2004 in the 2011 review but excluded it from this review update because further assessment revealed that the study did not meet our
inclusion criteria. In addition, we included a new study in this update (Chikobvu 2000).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Pregnancy Complications, Infectious; HIV Infections [mortality; prevention & control; ∗transmission]; Infectious Disease Transmis-
sion, Vertical [∗prevention & control]; Randomized Controlled Trials as Topic; Treatment Outcome; Vitamin A [∗administration &
dosage]; Vitamin A Deficiency [∗complications; drug therapy]; Vitamins [∗administration & dosage]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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